These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31964532)

  • 1. Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions.
    Nishida S; Matsumura T; Senokuchi T; Murakami-Nishida S; Ishii N; Morita Y; Yagi Y; Motoshima H; Kondo T; Araki E
    Biochem Biophys Res Commun; 2020 Mar; 524(1):8-15. PubMed ID: 31964532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization.
    Zhuge F; Ni Y; Nagashimada M; Nagata N; Xu L; Mukaida N; Kaneko S; Ota T
    Diabetes; 2016 Oct; 65(10):2966-79. PubMed ID: 27445264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DPP-4 Inhibitor Linagliptin Ameliorates Oxidized LDL-Induced THP-1 Macrophage Foam Cell Formation and Inflammation.
    Wang H; Li Y; Zhang X; Xu Z; Zhou J; Shang W
    Drug Des Devel Ther; 2020; 14():3929-3940. PubMed ID: 33061298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A
    Virta J; Hellberg S; Liljenbäck H; Ståhle M; Silvola JMU; Huusko J; Söderström M; Knuuti J; Nuutila P; Ylä-Herttuala S; Gomez MF; Roivainen A; Saraste A
    Atherosclerosis; 2020 Jul; 305():64-72. PubMed ID: 32386751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
    Schürmann C; Linke A; Engelmann-Pilger K; Steinmetz C; Mark M; Pfeilschifter J; Klein T; Frank S
    J Pharmacol Exp Ther; 2012 Jul; 342(1):71-80. PubMed ID: 22493041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice.
    Aroor AR; Habibi J; Kandikattu HK; Garro-Kacher M; Barron B; Chen D; Hayden MR; Whaley-Connell A; Bender SB; Klein T; Padilla J; Sowers JR; Chandrasekar B; DeMarco VG
    Cardiovasc Diabetol; 2017 May; 16(1):61. PubMed ID: 28476142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
    Yamaguchi T; Watanabe A; Tanaka M; Shiota M; Osada-Oka M; Sano S; Yoshiyama M; Miura K; Kitajima S; Matsunaga S; Tomita S; Iwao H; Izumi Y
    J Pharmacol Sci; 2019 Feb; 139(2):112-119. PubMed ID: 30638989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
    Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
    Vascul Pharmacol; 2016 Apr; 79():16-23. PubMed ID: 26277250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.
    Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
    Vascul Pharmacol; 2017 Sep; 96-98():19-25. PubMed ID: 28347868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo.
    Ishida M; Shen WR; Kimura K; Kishikawa A; Shima K; Ogawa S; Qi J; Ohori F; Noguchi T; Marahleh A; Kitaura H
    Biomed Pharmacother; 2019 Jan; 109():242-253. PubMed ID: 30396082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho-/- mice.
    Hasegawa Y; Hayashi K; Takemoto Y; Cheng C; Takane K; Lin B; Komohara Y; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2017 Dec; 16(1):154. PubMed ID: 29195509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice.
    Silva-Veiga FM; Miranda CS; Vasques-Monteiro IML; Souza-Tavares H; Martins FF; Daleprane JB; Souza-Mello V
    World J Gastroenterol; 2022 May; 28(17):1814-1829. PubMed ID: 35633911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
    Hirano T; Yamashita S; Takahashi M; Hashimoto H; Mori Y; Goto M
    Metabolism; 2016 Jun; 65(6):893-903. PubMed ID: 27173468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway.
    Chiazza F; Tammen H; Pintana H; Lietzau G; Collino M; Nyström T; Klein T; Darsalia V; Patrone C
    Cardiovasc Diabetol; 2018 May; 17(1):60. PubMed ID: 29776406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
    Kanasaki K
    Clin Sci (Lond); 2018 Feb; 132(4):489-507. PubMed ID: 29491123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages.
    Hiromura M; Nohtomi K; Mori Y; Kataoka H; Sugano M; Ohnuma K; Kuwata H; Hirano T
    Biochem Biophys Res Commun; 2018 Jan; 495(1):223-229. PubMed ID: 29113797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
    Tsuprykov O; Ando R; Reichetzeder C; von Websky K; Antonenko V; Sharkovska Y; Chaykovska L; Rahnenführer J; Hasan AA; Tammen H; Alter M; Klein T; Ueda S; Yamagishi SI; Okuda S; Hocher B
    Kidney Int; 2016 May; 89(5):1049-1061. PubMed ID: 27083282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DPP-4 Inhibition with Anagliptin Reduces Lipotoxicity-Induced Insulin Resistance and Steatohepatitis in Male Mice.
    Sakai Y; Chen G; Ni Y; Zhuge F; Xu L; Nagata N; Kaneko S; Ota T; Nagashimada M
    Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32790863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy.
    Hasan AA; von Websky K; Reichetzeder C; Tsuprykov O; Gaballa MMS; Guo J; Zeng S; Delić D; Tammen H; Klein T; Kleuser B; Hocher B
    Kidney Int; 2019 Jun; 95(6):1373-1388. PubMed ID: 30979564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs - An Ab Initio Fragment Molecular Orbital Study.
    Arulmozhiraja S; Matsuo N; Ishitsubo E; Okazaki S; Shimano H; Tokiwa H
    PLoS One; 2016; 11(11):e0166275. PubMed ID: 27832184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.